Form PTO-1449 (REV. 1/06)		US DEPL OF COMMERCE PATENT & TRADEMARK OFFICE  IATION DISCLOSURE STATEMENT		ATTY DOCKET NO.    SEP 2 1 2006   APPLICATION NO. 10/580,532					
(Use several sheets if necessary)					APPLICANTS Taiji FURUKAWA et al.				
				FILING May 25					
			J.S. PATEN	T DOCUM	IENTS				
Examiner Initials	Cite No.	Document Number	Da	ite	Na	me			
	1	4,576,934	3/18/19	86	Seto et al.				
		FOR	EIGN PATI	ENT DOC	UMENTS				
Examiner Initials	Cite No.	Document Number	Da	ate	Country	With English Abstract	With English Translatio		
	2	WO 03/062201 A1	7/31/200	13	WIPO				
	3	EP 230 944 A1	8/5/1987		Europe				
	4	JP A 1-275591	11/6/198	19	Japan	х			
	5	WO 2004/024153	3/25/200	14	WIPO				
	5	JP A 60-69089	4/19/198	15	Japan	х			
	7	JP A 63-233992	5/2\$/199	10	Japan	x			
	7	JP A 61-030591	2/12/198	16	Japan	х			
	5	JP A 61-063688	4/1/1986	,	Japan	х			
	16	JP A 62-169795	7/25/198	37	Japan	х			
	16	JP A 62-169795	7/25/198	37	Japan	х			
	12	JP A 58-167569	10/3/198	33	Japan	х			
	14	JP A 55-000301	1/5/1980	)	Japan	х			
	14	JP A 62-174017	7/30/198	17	Japan	х			
	16	JP A 60-097956	5/31/198	35	Japan	x			
	16	JP A 49-108082	10/14/19	774	Japan	х			
	14	JP A 2-138221	5/28/199	90	Japan	х			
	16	JP A 2002-226376	8/14/200	)2	Japan	х	x		
							-		
			OTHER D	OCUME	NTS				
Examiner Initials	Cite No.	(Including Au	thor, Title,	Date, Pert	inent Pages, etc.)				
XAMINER						ATE CONSIDERE			

and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 3

Form PTO-1449 US Dept. of Commerce (REV. 1/06) PATENT & TRADEMARK OFFICE			ATTY DOCKET NO. 128186		APPLICATION NO. 10/580,532				
INFORMATION DISCLOSURE STATEMENT									
(Use several sheets if necessary)					APPLICANTS Taiji FURUKAWA et al.				
				FILING May 25					
U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number	Da	Date Name					
FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number	Date		Country		With English Abstract	With English Translation	
OTHER DOCUMENTS									
Examiner Initials									
	19	K. HARADA et al.; "Clinical Efficacy of Efonidipine Hydrochloride, a T-type Calcium Channel Inhibitor, on Sympathetic Activities - Examination Using Spectral Analysis of Heart Rate/Blood Pressure Variables and <sup>179</sup> l-Metaiodobenzy/guanidine Myocardial Scientippshy," Circuitotion Journal, Vol. 67, February 2003, pp. 139-145.							
	20	P. KUMAR et al.; "Synthesis and Evaluation of a New Class of Nifedipine Analogs with T-Type Calcium Channel Blocking Activity;" Molecular Pharmacology, 2002, Vol. 61, No. 3, pp. 649-658.							
	21	H. SUZUKI et al.; "Antihypertensive Effects and Reducing Effects on Proteinuria of Cilnidipine on Hypertension Patients with Nephrosclerosis;" Therapeutic Research, 2000, Vol. 21, No. 4, pp. 760-762.							
	22	D. BILICI et al.; "Protective Effect of T-Type Calcium Channel Blocker in Histamine-Induced Paw Inflammation in Rat;" Pharmacological Research, 2001, Vol. 44, No. 6, pp. 527-531.							
	23	C. BAYLIS et al.; "Comparison of L-Type and Mixed L- and T-Type Calcium Channel Blockers on Kidney Injury Caused by Deoxycorticosterone-Salt Hypertension in Rats;" American Journal of Kidney Diseases, 2001, Vol. 38, No. 6, pp. 1292-1297.							
	24 W. MCCALMONT et al.; "Design, Synthesis, and Biological Evaluation of Novel T-Type Calcium Channel Antagonists;" Bioorganic and Medicinal Chemistry Letters, 2004, Vol. 14, No. 14, pp. 3691-3695.							nists;"	
	D. PORCELLO; "Actions of U-92032, a Type CA <sup>2+</sup> Channel Antagonist, Support a Functional Linkage Between I <sub>1</sub> and Slow Intrathalamic Rhythms;" J Neurophysiol., 2003, Vol. 89, No. 1, pp. 177-185.							nd Slow	
	26								
	27	P. MULDER et al.; "Increased Survival After Long-Term Treatment with Mibefrafil, a Selective T-Channel Calcium Antagonist, in Heart Failure"; JACC; Vol. 29, No. 2; February 1997; pp. 416-421.							
	J. VILLAME et al.; "Effects of Mibefradil, a T- and L-Type Calcium Channel Blocker, on Cardiac Remodeling in the U. X7.1 Cardiomyopathic Hamster"; Cardiovascular Drugs and Therapy; Vol. 15; 2001; pp. 41-48.							g in the UM-	
- 0.0	29 S. FAREH et al.; "The T-Type Ca <sup>3*</sup> Channel Blocker Mibefradil Prevents the Development of a Substrate for Atrial Fibrillation by Tachycardia-Induced Atrial Remodeling in Dogs"; Circulation; Vol. 100; November 23, 1999; pp. 2191-2197.								
EXAMINER DATE CONSIDERED									
Examiner:	Initial if	citation considered, whether or not citat onsidered. Include copy of this form wit	ion is in co	nformanc	e with M.P.E.P. 609; draw line through to applicant.	gh cita	ation if not in	conformance	

	Sheet	3	of	3
--	-------	---	----	---

		US Dept. of Cor PATENT & TRADEMARK C		ATTY DOCKET NO. 128186		APPLICATION NO. 10/580,532			
INFORMATION DISCLOSURE STATEMENT									
(Use several sheets if necessary)					APPLICANTS Taiji FURUKAWA et al.				
FILING DATE May 25, 2006									
		U.	S. PATEN	T DOCUN	IENTS				
Examiner Initials	Cite No.	Document Number	Da	ite Name					
FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number	Date		Country	With English Abstract	With English Translation		
			OTHER D	OCUME	NTS				
Examiner Initials	Cite No.								
	30	G. NOLL et al.; "Comparative Phramacological Properties among Calcium Channel Blockers: T-Channel versus L-Channel Blockade"; Cardiology; Vol. 89; Supp. 1; 1998, pp. 10-15.							
	31	S. LENGLET et al.; "Activation of 5-HT, Receptor in Rat Glomerulosa Cells is Associated with an Increase in Adenylyl Cyclase Activity and Calcium Influx through T-Type Calcium Channels"; Endocrinology; Vol. 143, No. 5; pp. 1748-1760.							
	32	J. MCCALLUM et al.; "Loss of T-type Calcium Current in Sensory Neurons of Rats with Neuropathic Pain";  Anesthesiology; Vol. 98, No. 1; 2003; pp. 209-216.							
					· · · · · · · · · · · · · · · · · · ·				
EXAMINER /Emily Bernhardt/ DATE CONSIDERED 09/29/2009						/2009			
Examiner:	Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance								